Drugs / TLC-6740
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05822544 | Apr 2023 → Feb 2026 overdue | obesity disorder, type 2 diabetes mellitus | OrsoBio, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TLC-6740 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05822544 ↗ |
| Route | Oral | “Oral solution of TLC-6740” NCT05822544 ↗ |